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Abstract
Kinetic models have a great potential for metabolic engineering applications.
They can be used for testing which genetic and regulatory modifications
can increase the production of metabolites of interest, while simultaneously
monitoring other key functions of the host organism. This work presents
a methodology for increasing productivity in biotechnological processes ex-
ploiting dynamic models. It uses multi-objective dynamic optimization to
identify the combination of targets (enzymatic modifications) and the degree
of up- or down-regulation that must be performed in order to optimize a set
of pre-defined performance metrics subject to process constraints. The capa-
bilities of the approach are demonstrated on a realistic and computationally
challenging application: a large-scale metabolic model of Chinese Hamster
Ovary cells (CHO), which are used for antibody production in a fed-batch
process. The proposed methodology manages to provide a sustained and
robust growth in CHO cells, increasing productivity while simultaneously in-
creasing biomass production, product titer, and keeping the concentrations
of lactate and ammonia at low values. The approach presented here can
be used for optimizing metabolic models by finding the best combination of
targets and their optimal level of up/down-regulation. Furthermore, it can
accommodate additional trade-offs and constraints with great flexibility.
Keywords: dynamic modelling, multi-objective optimization, large-scale,
metabolic engineering, target identification, up/down-regulation
Preprint submitted to Journal of Biotechnology October 21, 2015
1. Introduction
Model-based approaches can be used to improve biotechnological pro-
cesses. In model-based metabolic engineering, mathematical models are used
to guide the optimization of metabolic processes aiming at enhanced produc-
tion of a certain compound. Model-based metabolic engineering techniques
can be broadly classified into two categories, depending on the type of models
used: static or kinetic.
Constraint-based methods such as flux balance analysis (FBA) (Varma
and Palsson, 1994; Kauffman et al., 2003; Orth et al., 2010) use static models
to calculate steady-state fluxes. These models focus on stoichiometry and do
not include kinetic detail, and as a consequence they cannot predict how
global metabolic behavior emerges from dynamic concentration changes of
cellular components. Recent reviews of the state of the art in constraint-
based modeling for metabolic engineering applications can be found in Long
et al. (2015); King et al. (2015); Machado and Herrgard (2015).
Kinetic models, on the other hand, allow for more detailed predictions.
They can be used for calculating the alterations needed to optimize quantities
such as the flux or yield of compounds of interest, while keeping the other
functions of the host organism to a minimal, but essential, level (Smallbone
and Mendes, 2013; Almquist et al., 2014; Song et al., 2013; Link et al., 2014).
Early on, extensions of constraint-based methods were developed with the
aim of increasing the accuracy of predictions in cases where dynamic adap-
tations play an important role. Dynamic Flux Balance Analysis (dFBA) is
an extension of FBA that takes into account the rate of change of flux con-
straints, which has been shown to improve predictions of the dynamics of
diauxic growth (Mahadevan et al., 2002). In related applications, Henson
and coworkers used dFBA for optimizing ethanol production both in S. cere-
visiae fermentation (Hjersted and Henson, 2006) and in a batch co-culture of
two yeasts (Hanly et al., 2013). More recently, the DySScO (Dynamic strain
scanning optimization) strategy (Zhuang et al., 2013) has integrated dFBA
with strain design algorithms, allowing optimizing not only yield but also
product titer and productivity and taking into account economic considera-
tions such as the price difference between product and feedstock.
Furthermore, in recent years a number of approaches have been presented
for exploiting kinetic models in metabolic engineering applications. Nikolaev
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proposed a mixed-integer non-linear programming method for optimizing the
enzyme levels and enzyme regulatory structure of metabolic models (Niko-
laev, 2010) and applied it to a well-known kinetic reconstruction of E. coli
(Chassagnole et al., 2002). Nolan and Lee presented a kinetic model of CHO
cell metabolism (Nolan and Lee, 2011) and used it for metabolic engineering
purposes (Nolan and Lee, 2012). They defined a set of possible modifications
of certain process variables and gene knockdowns, allowing for a set of fixed
levels of enzyme down-regulation. After performing the resulting simulations
and selecting the feasible solutions, they obtained an ordered list of the best
ones. Chowdhury and coworkers presented an optimization-based strain de-
sign framework, k-OptForce (Chowdhury et al., 2014), which is suitable for
stoichiometric-based models for which mechanistic kinetic details are known
for some equations. The methodology was applied to a kinetic model of E.
coli to improve succinate yield (Khodayari et al., 2014); interestingly, how-
ever, this study also showed that predictions made by kinetic models may be
worse than those obtained by FBA if the phenotype is significantly different.
Additional degrees of freedom can be achieved by implementing control
strategies that change during the time course of the bioprocess, in response
to changes in the process conditions (Venayak et al., 2015); for example, via
dynamic optimal control of enzyme levels (Brockman and Prather, 2015).
Recent applications of this strategy include, for example, the dynamic regu-
lation of malonyl-CoA pools for improving fatty acid production (Xu et al.,
2014).
Despite many significant advances, the use of realistic large-scale dynamic
models is still hindered by a number of reasons: there are few of those models
available, the experimental data required for their calibration is scarce, the
associated optimization problems are computationally hard (Villaverde et al.,
2015b), and there is usually large uncertainty regarding the detailed char-
acterization of enzyme kinetics and enzyme regulation (Chakrabarti et al.,
2013). For these reasons the use of kinetic models is not widespread in the
biotechnology industry yet, although recent reviews strongly advocate for
their exploitation (Almquist et al., 2014; Song et al., 2013; Link et al., 2014).
To make this vision come true, new methodologies will be needed to overcome
the associated difficulties.
With this aim we present here an approach that includes several contri-
butions. The proposed methodology uses dynamic optimization to identify
the combination of targets (i.e. enzymatic modifications) and determines the
degree of up- or down-regulation that must be performed on them. It does
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so by applying a multi-objective optimization approach to obtain a Pareto
front of solutions, from which the preferred trade-off between improvement
in productivity–or, more generally, in any objective defined as a dynamic
function of the system variables–and intervention effort can be selected. The
control vector parameterization approach together with state of the art op-
timizers are used to solve the dynamic optimization problem. Furthermore,
the method can accommodate additional requirements, such as keeping the
concentrations of some metabolites within certain bounds throughout the
process.
We demonstrate the capabilities of this approach by applying it to a
challenging problem, the optimization of Chinese Hamster Ovary (CHO)
cells for antibody production. Optimization of CHO strains is taking on
greater significance in the industry. The emphasis is put on obtaining strains
with robust growth and high metabolic product formation. However, the
process of identifying robust targets is more challenging for CHO cells than
for other hosts such as E. coli or yeast cells, due to their sensitive nature.
Furthermore, product quality plays a key role since products from CHO
cells are often used for the application in the human body (e.g. biologics).
An in silico approach offers the possibility to remove several obstacles at
once by generating a comprehensive kinetic model of the CHO metabolism,
calibrating the CHO model to real process conditions, and optimizing the
cell such that gene expression levels lead to improvement of multiple targets.
As has been already mentioned, kinetic models of CHO cells have been
used for metabolic engineering purposes before (Nolan and Lee, 2012). How-
ever, in Nolan and Lee (2012) only gene knockdown was considered, and the
allowed levels of enzyme down-regulation were fixed: either the nominal value
or its 20% could be chosen, but no intermediate values. Furthermore, the
solution space was explored by carrying out many simulations with different
combinations of modifications, without applying optimization techniques. In
contrast, here we allow for down- and up-regulation, explore the continuous
range of values, and apply state of the art optimization algorithms to make
sure that the solution space is thoroughly and efficiently explored. We also
use a new, more complete CHO cells model. In several ways the approach pre-
sented here has more similarities with the one by Nikolaev (2010). However,
compared to that work, we present key contributions: the ability to accom-
modate both end-point (final time) and path (throughout process duration)
constraints with great flexibility, and its dynamic optimization formulation
which allows designing time-varying inputs in a natural way.
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2. Methods
A graphical overview of the methodology is shown in Figure 1. A detailed
description is provided in the following subsections.
2.1. Objectives for bioprocess optimization
We begin the presentation of the methodology by defining some terms
frequently used in bioprocess engineering, and discussing the implications
that the choice of the objective function has in the optimization outcomes.
Yield, Yij, is the ratio between the produced amount (mass) of a target
metabolite j and the consumed amount of a substrate i, that is:
Yij =
m
p
j
mci
(1)
The productivity is the industrial measure for the economic viability of
a bioprocess. It is defined as the rate at which the target metabolites are
produced. Here we focus on the specific productivity, which is the cell specific
production rate [g/(gDW·h)]. It is a measure of the performance of the cell
to produce the desired product. The specific productivity multiplied with the
cell concentration in the fermenter is the so called volumetric productivity
[g/(l·h)]. It represents a performance measure at the reactor level (Song
et al., 2013).
Ideally, bioprocess optimization should aim at maximizing yield and pro-
ductivity simultaneously. However, it is important to realize that maximizing
yield does not necessarily imply maximizing productivity, because increasing
product yield often leads to impaired growth of the microorganism (Song
et al., 2013).
These are definitions typically found in the literature. However, some
variants of them can also be used. For example, it should be taken into
account that rate is an instantaneous quantity. Therefore, in a fed-batch
process where the rate is not constant, it makes sense to maximize the inte-
gral of the rate, in which case the (volumetric) productivity would have units
of concentration, not of rate (concentration/time). Note that if the reactor
volume is constant, it is equivalent to speak of concentrations and masses.
Maximizing the integral of the rate tends to maximize the total amount of
substrate consumed during the process, instead of the instantaneous sub-
strate consumption rate.
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In the present work we choose to maximize a productivity term defined
as the integral of the rate of production of the target metabolite,
P =
∫ tf
t0
rj(t)dt (2)
where rj(t) is the instantaneous production rate [µmol/(gDW·h)] of the
metabolite j, which in the case study used in this work is antibody formation
rate, and P has units [µmol/gDW].
Finally, we note that it is also possible to perform a more detailed eco-
nomic analysis of the process by including other factors, such as material
costs and operation costs. The resulting benefit can then be expressed as
the return on investment (ROI), which is defined as the net profit obtained
divided by the cost of investment.
2.2. Problem formulation: optimization of kinetic models for metabolic en-
gineering
The general problem addressed here is formulated as a dynamic optimiza-
tion, where the objective is to find the decision variables which optimize a
pre-defined performance index subject to the dynamic constraints and other
possible bounds.
Mathematically, this is formulated as follows:
min
v,u(t),tf
J(x, v, u) (3)
subject to the following constraints:
dx(t)
dt
= f (x(t), v, u(t), t, p) (4)
x(t0) = x0 (5)
heq(x(t), v, u(t)) = 0 (6)
hin(x(t), v, u(t)) ≤ 0 (7)
pheq(x(ti), v, u(ti)) = 0 (8)
phin(x(ti), v, u(ti)) ≤ 0 (9)
vL ≤ v ≤ vU (10)
uL ≤ u ≤ uU (11)
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where J(x, v, u) is the performance index to maximize, t is the time vari-
able, x(t) is the vector of state variables with initial conditions x0, v is the
vector of time-invariant decision variables, u(t) is the vector of time-varying
decision variables (v and u are also called controls), f is the set of differential
and algebraic equality constraints describing the system dynamics (that is,
the nonlinear system model), p is the vector of model parameters (constants),
heq and hin are equality and inequality path constraints that express addi-
tional requirements for the system performance, pheq and phin are equality
and inequality point constraints that must be verified at a given time (such
as the final time, tf ), and v
L, vU , uL, and uU are lower and upper bounds
for the vectors of decision variables v and u.
The equations above define the general formulation of a dynamic opti-
mization problem. For the case of a metabolic engineering application as the
one considered here, they correspond to the following concepts:
• The objective function to optimize, J , is defined as the integral of the
formation rate of antibody, as in equation (2).
• The decision variables v are the enzyme levels. In the present appli-
cation they are kept constant during the time course of the operation,
and no time-varying decision variables u(t) are considered. However,
the methodology presented here can also be applied to the case of vari-
ables that vary in time–that is, control profiles consisting of series of
steps, pulses or ramps can be taken into consideration.
• Apart from the differential equations defining the model dynamics, f ,
the additional constraints included in the formulation are some realistic
lower and upper bounds for the state variables. In the application
reported here we impose: (i) lower bounds on some concentrations as
end-point constraints, phin, that is, conditions that are only checked at
the end of the time courses (to ensure that some key metabolites are
not exhausted during the process); and (ii) lower and upper bounds for
other quantities as path constraints, hin, that is, conditions that must
be satisfied at all times (to ensure that some concentrations are always
kept below or above some desired reference level). The choice of the
particular type of constraints is application-dependent and should be
made with attention to the process characteristics. The methodology
presented here is sufficiently general to accommodate any combination
of constraints.
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Using a numerical approach named control vector parametrization (CVP)
(Vassiliadis, 1993) the original dynamic optimization problem is split into
two sub-problems: an outer non-linear programming problem (NLP), and
an inner initial value problem (IVP). The outer problem finds the optimal
decision variables, that is, it optimizes the enzyme levels. The inner problem
integrates the system dynamics. This approach has been recently shown to
be able to predict activation in metabolic pathways (de Hijas-Liste et al.,
2014).
Note that, in general, the outer problem could be formulated as a mixed-
integer nonlinear programming problem (MINLP), where the aim would be
to find (i) the set of decision variables that should be modified (discrete
problem) and (ii) their optimal values (continuous problem). Instead, to
facilitate the implementation, the outer optimization problem is solved here
as a NLP, which is a relaxation of the more general MINLP. That is, we
solve a continuous optimization problem where all the decision variables
are in principle allowed to depart from the reference values. Not specifying a
bound on the number of possible modifications would tend to lead to solutions
where all the possible decision variables are modified. Hence to reduce the
number of modified decision variables to a manageable quantity we adopt a
multi-objective optimization approach using the ǫ-constraint method, whose
aim is to add a penalty to the modification effort. It is described in detail in
the following subsection.
We note that, since the models we are handling are non-linear and large-
scale, the outer optimization problem is multimodal and very challenging to
solve. Therefore it is necessary to use proper global optimization methods
(Banga et al., 2005). Specifically, we have used here the eSS optimization
metaheuristic (Egea et al., 2010) implemented in the AMIGO toolbox (Balsa-
Canto and Banga, 2011). Furthermore, since eSS is a hybrid method that
can make use of local methods to accelerate performance, we have used it in
combination with SOLNP (Yinyu, 1990) as a local solver.
Importantly, we remark that the methodology allows for the precise tun-
ing of the optimal enzyme levels v, that is, the exact amount of up- and
down-regulation that must be performed to optimize the performance. This
is a different and more powerful tool than simply finding the optimal knock-
downs, or even choosing the optimal level among a pre-specified set.
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2.3. Multi-objective optimization
The problem considered in this work involves a trade-off between two
conflicting objectives: on the one hand the aim is to maximize productivity,
while on the other hand we wish to keep the number of interventions (i.e.
enzymatic modifications) as small as possible. To address this problem prop-
erly we modify the formulation presented in the preceding subsection, and
consider the performance index in equation (3) as a set of two cost functions:
J(x, v) =
[
J1(x, v)
J2(x, v)
]
(12)
where the first objective to be optimized (J1) is the productivity defined
in equation (2). The second objective (J2) is the modification effort,
J2 = ‖v − v0‖ (13)
where v is the vector of decision variables (enzyme levels) and v0 is the
reference vector of decision variables, that is, the enzymatic levels of the wild
type cell. We choose as norm the absolute value,
J2 = ‖v − v0‖ =
n∑
i=1
|v(i)− v0(i)| (14)
where n is the vector length and v(i) is its ith element.
To appropriately address the goal of optimizing two conflicting objectives
simultaneously we adopt a multicriteria optimization approach. The outcome
of a multicriteria or multiobjective optimization (MOO) procedure is the so-
called Pareto front of non-dominated solutions. Each of the solutions in the
Pareto front represents an optimal trade-off between both objectives, J1 and
J2. Thus, it is not possible to improve one of them without worsening the
other.
We obtain the Pareto front using the ǫ-constraint method (Haimes et al.,
1971). This approach is conceptually simple: it consists of performing several
optimizations, each of which optimizes one objective (i.e. maximize produc-
tivity, J1) while using the remaining objective as an inequality constraint
(i.e. keep the modification effort, J2, below a maximum value). Setting J2 to
a different value in every optimization (or in other words, setting a different
upper bound for the inequality constraint) leads to different solutions, each
of which represents the maximum productivity achievable for the allowed
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modification effort. The solutions found in this way constitute the Pareto
front. More details about the application of this method to the CHO cells
model are given in section 3.2.
In our formulation, all the decision variables v (enzyme levels) are in
principle allowed to be modified, that is, the number of interventions is not
selected a priori. Since the ǫ constraint imposes an upper limit on the overall
deviation from the reference levels, the total amount of modification becomes
a limited resource. Hence the optimization algorithm will concentrate on
modifying the enzymes which exert a greater influence on the productivity,
while leaving the less influential unmodified. This will result in few enzyme
levels with significant modifications, along with many others with very small
modifications (the proportion of enzymes in one or other group will depend on
the chosen value of the ǫ constraint). Due to this fact the whole optimization
procedure is carried out in two steps:
1. Calculation of the Pareto front and selection of the preferred trade-off
solution: perform m optimizations corresponding to different levels of
ǫ, i.e. ǫ = [ǫ1, ǫ2, . . . , ǫm]. This results in a Pareto front consisting of a
set of m solutions, each of which corresponds to an optimal trade-off
between productivity enhancement and modification effort. From the
Pareto front we choose our preferred solution, taking into account the
number of enzymatic modifications that is reasonable to perform.
2. Refinement of the preferred solution: take the solution selected in the
previous step and reset all the enzyme levels whose values were not
significantly altered during optimization to their reference values. This
will usually result in a solution whose performance is only slightly worse
than the one found in the optimizations. This new solution–to which
we refer here as “fixed” solution for convenience–is then taken as the
starting point for a subsequent refinement through a new optimization,
in which the only decision variables allowed to change are the ones that
underwent significant modifications in the previous step.
The outcome of this procedure is a model which optimizes productivity while
satisfying other constraints, with an adjustable number of interventions.
Finally, we note that unlike other procedures such as the weighted sum
approach, the ǫ-constraint method is able to identify a nonconvex boundary.
An example of MOO of biological networks using the ǫ-constraint method
(without involving integration of kinetic models) can be found in (Sendin
et al., 2010).
10
3. Results and Discussion
3.1. Case study: CHO cell model for antibody production
We applied the proposed dynamic optimization approach to optimize an-
tibody production in Chinese Hamster Ovary cells (CHO). To this end, we ex-
tended a recently presented compartmented large-scale kinetic model of CHO
metabolism (Villaverde et al., 2015a), which is included in the BioPreDyn-
bench collection (Villaverde et al., 2015b). We took the biomass and anti-
body composition and experimental data from Nolan and Lee (2011). To
be able to describe the phenotype, we added the uptake, consumption, for-
mation and degradation of multiple amino acids in the model. The ODE
model comprises now reactions from the central carbon metabolism as well
as elements from the amino acids metabolism, mitochondrial respiration, and
generation of unwanted by-products (lactate and ammonia). A diagram of
the network is shown in Figure 2. It involves 54 balanced compounds and
45 reactions (cf. supplementary table S1). All reactions are modeled with
linlog kinetics, with exception of biomass and antibody formation, for which
irreversible Michaelis-Menten kinetics are chosen to avoid reversibility due
to accumulating product effects. The model has a total of 209 kinetic pa-
rameters and 44 possible enzymatic modifications. The model simulates a
bioprocess consisting of two steps: first, a batch process of 70 hours, followed
by a fed-batch process lasting for additional 160 hours, during which glucose,
cysteine, serine and glutamine are fed.
In order to speed-up the computations, the model dynamics were im-
plemented in FORTRAN, and a Matlab file was created for interfacing the
model with the AMIGO Matlab toolbox (Balsa-Canto and Banga, 2011).
Integration was performed with the RADAU5 solver (Hairer and Wanner,
2005) enforcing tight integration tolerances (relative: 10−9, absolute: 10−12).
Using the scatter search optimization metaheuristic included in the AMIGO
toolbox, we calibrated the model with experimental data taken from (Nolan
and Lee, 2011), which consists of 11 time points for each of the 13 measured
metabolites. We managed to obtain a good fit–shown in Figure 3–which is
qualitatively similar to the one reported in the original publication.
We note that, since the data set used for model calibration is relatively
small compared to the number of unknown parameters, several parameter
vectors can lead to similarly good fits. This fact, which denotes poor prac-
tical identifiability, does not necessarily prevent models from making useful
predictions (Cedersund, 2012), and it can be addressed with an ensemble
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modelling approach such as the one in (Villaverde et al., 2015a), among
other possibilities. Future work will involve more detailed analyses of the
uncertainty in model calibration and its consequences for model predictions.
3.2. Multi-objective optimization of CHO cells
After calibrating the model we applied the procedure presented in the
Methods section. Recall that in this MOO problem we consider two ob-
jectives: achieving maximal productivity with a minimum of interventions.
With the ǫ-constraint method this means maximizing the first objective J1,
which is the productivity defined in equation (2), while using the second
objective J2 as an inequality constraint. The second objective J2 is the mod-
ification effort defined in equations (13) and (14). In this application the ref-
erence decision variables v0 are normalized to a unit value, and the elements
of the vector v are allowed to change during optimization in the range [0.2,2].
This application does not require the definition of equality constraints as in
equations (6)-(8), although they could be included if necessary. Regarding
inequality constraints, we define several end-point constraints as in equation
(9), to enforce that:
1. Product titer (i.e. antibody concentration at final time) and biomass
are higher in the optimal cell than in the wild type cell. This constraint
is required because optimizing productivity may lead to reduced pro-
duction of biomass, and increased productivity does not always corre-
late directly to increased product titer.
2. The concentrations of certain metabolites at final time are kept above
zero, to ensure that they are not exhausted during the process.
Finally, we also define some path constraints which must be fulfilled during
the whole time course of the process:
1. The concentrations of ammonia and lactate are always kept below a
reference value.
2. The energy charge of the cell is always kept above a reference level.
After defining the problem in this way, we optimized the model for several
values of ǫ and obtained the Pareto front shown in Figure 4. As expected, as
the number of allowed modifications increases, so does the achievable objec-
tive (i.e. productivity). However, we are interested in a solution that can be
obtained with a reasonable number of enzymatic modifications, typically 4 or
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5. Hence from the set of obtained solutions we selected the one correspond-
ing to ǫ = 2, which presents only 4 significant modifications and manages to
improve productivity while satisfying the remaining constraints, as desired.
By “significant” we refer to changes larger than 10% with respect to the
reference value of one, that is, values in the range [0.9,1.1]. The identified
modifications and their optimal values are shown on Figure 4 and in column
(II) of Table 1.
Note that the value of ǫ that leads to a particular number of significant
modifications (in this case, four) is not known a priori, because it depends on
the way that the “modification budget” represented by ǫ is spent. Recall that
ǫ is not the number of modifications, but the sum of the deviations between
the reference enzyme levels and the modified enzyme levels. Thus, a value
of ǫ = 2 could also lead to only 3 significant modifications instead of 4, for
example.
3.3. Refinement of the initial solution
The solution reported in the previous subsection contained a large number
of decision variables which are only slightly modified, that is, their values lie
in the range [0.9,1.1]. After fixing their values to the initial reference value
of one, we define a new optimization where we only allow to change the four
enzyme levels listed above. We take their optimized values as the initial point
for a subsequent optimization to refine this solution, arriving at the set of
values shown in column (III) of Table 1.
The most important process outcomes obtained with these new levels are
shown in Figure 5, from which it is clear that the optimization procedure
succeeds in improving the original system. It should be noted that the quan-
tities in the upper row (productivity, antibody concentration, and amount of
biomass) should be increased with respect to the wild type, while the quanti-
ties in the lower row (concentrations of lactate and ammonia) should remain
low. The desired outputs are achieved in both cases; notably, the optimized
model avoids the peaks in ammonia and lactate concentration, while at the
same time providing a sustained and robust growth.
3.4. Biological interpretation of the solution
The optimal enzyme modifications found were: glutamate dehydrogenase,
glutamate-ammonia ligase (also known as glutamine synthetase), glucose
phosphate isomerase, and mitochondrial glutamate carrier, Slc24a18/Gc2.
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One of these modifications is actually quite common: a knockout or knock-
down of the glutamine synthetase, as predicted in our approach, is found in
many high-producer CHO cell mutants (Fan et al., 2012, 2013). Ammonia
inhibits the growth of CHO cells (Zhang et al., 2006) and in mammalian
cells the capacity for ammonia removal is higher in the absence than in the
presence of glutamine (Choi et al., 2000). Therefore a glutamine synthetase
deficiency results in lower ammonia level, and has a positive effect on growth
(Zhang et al., 2006). On the other hand, the proposed downregulation of
glucose-6-phosphate isomerase leads to decreased glycolytic fluxes resulting
in a reduction of lactate. Experimentally the loss of glucose-6-phosphate
isomerase activity resulted in a temperature sensitivity and severe reduction
in the synthesis of glycerolipids due to a reduction in phosphatidate phos-
phatase (Haller et al., 2011). Furthermore, a knockdown reduces the carbon
supply which is needed to cover energy needs of the cell. Hence, at first
sight the knockdown modification of the glucose-6-phosphate isomerase pro-
posed by our method is counterintuitive. However, the predicted glutamate
dehydrogenase overexpression helps to solve the energy dilemma. The gluta-
mate dehydrogenase pathway is usually preferred when the energy demand
is not fulfilled because of glucose exhaustion (Altamirano et al., 2013). The
glutamate dehydrogenase pathway is also known to be more efficient than
the transaminase pathway (Altamirano et al., 2013). Furthermore, the over-
expression of the mitochondrial glutamate carrier Slc24a18/Gc2 increases
the import of glutamate into the mitochondrion. Thus, this combination of
targets manages to reduce lactate production (via glucose-6-phosphate iso-
merase knockdown), on the one hand, and on the other hand it fulfils the
modified energetic needs (Slc24a18/Gc2 and glutamate dehydrogenase over-
expression).
4. Conclusions
We have presented a methodology for increasing productivity in biotech-
nological processes exploiting dynamic models. The method identifies the
combination of targets (enzymatic modifications) and determines the exact
degree of up- or down-regulation that must be performed. This allows for
more flexibility than simply finding the optimal knock-outs, or even finding
the optimal regulation levels from a set of preset values. Furthermore, the
procedure can accommodate additional requirements, such as the need of
keeping the concentrations of some metabolites within certain bounds. Im-
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portantly, the multi-objective optimization approach that lies at the core of
the methodology applies a so-called ǫ-constraint technique, which generates
a Pareto front of nondominated solutions. Having a set of optimal solu-
tions instead of a single one allows to select the preferred trade-off between
improvement in productivity and number of required interventions.
We have illustrated the capabilities of the approach applying it to a large-
scale metabolic model of Chinese Hamster Ovary cells (CHO), which are used
for antibody production in a fed-batch process. Optimization of CHO strains,
with the double aim of achieving robust growth and high metabolic prod-
uct formation, is of great importance in the biotechnology industry, but the
sensitive nature of CHO cells makes it challenging to obtain robust predic-
tions. Here we showed that the proposed methodology manages to provide
a sustained and robust growth in CHO cells, increasing productivity while
simultaneously increasing biomass production, product titer, and keeping the
concentrations of lactate and ammonia at low values.
We noticed that keeping the process variables fixed for the optimized
strain limits possible improvements, since a new strain phenotype has al-
tered feeding requirements. Therefore, future work will involve exploring the
additional improvements that can be obtained by including the feed compo-
sition and volume as a time-varying decision variable, as well as the direct
solution of the resulting mixed-integer dynamic optimization problem. We
expect that the additional flexibility attained in this way will lead to sub-
stantial gains in productivity.
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Figure captions
Figure 1. Methodology. The diagram shows the main steps of the
method. Starting with a kinetic model, n optimizations are performed in
order to obtain a Pareto front of non-dominated solutions. From that set
of solutions the one with the preferred trade-off between modification effort
and performace improvement is selected. Finally, this solution is taken as the
starting point for a final optimization (refinement) in which only a reduced
subset of enzyme levels is allowed to change.
Figure 2. Metabolic network of the CHO cell model. It includes central
carbon metabolism, amino acid metabolism, mitochondrial respiration, and
generation of unwanted by-products.
Figure 3. Model calibration. Fits to the experimental data reported in
(Nolan and Lee, 2011).
Figure 4. Pareto front. The blue dots represent non-dominated solu-
tions, each of which presents an optimal trade-off between productivity (ver-
tical axis) and ǫ, the modification effort as defined in eq. (14) (horizontal
axis). From this set of obtained solutions we selected the one corresponding
to ǫ = 2, which presents the 4 significant modifications listed in the inserted
text box.
Figure 5. Final solution. Comparison of the time-courses of the key vari-
ables of the original wild type (red lines) and optimized (blue lines) solution.
Dotted lines represent upper bounds that are enforced as path constraints,
i.e., conditions that must be fulfilled during all the time course of the experi-
ment. Dashed lines represent lower bounds enforced as end-point constraints,
i.e. they are minimum values that must be achieved at final time.
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Tables
Table 1: Enzyme levels: original and optimal values.
Enzymatic (I) Original (II) Pareto front (III) Final refined
modifications values solution solution
Glutamate dehydrogenase 1.00 1.31 2.00
Glutamate-ammonia ligase 1.00 0.76 0.58
Glucose phosphate isomerase 1.00 0.30 0.26
Slc25a18/Gc2 1.00 1.50 2.00
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